| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey
|
Barrière, J.
|
|
|
32 |
5 |
p. 673-674
|
artikel
|
| 2 |
Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry
|
Kwon, D.H.
|
|
|
32 |
5 |
p. 678-679
|
artikel
|
| 3 |
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
|
Brufsky, A.
|
|
|
32 |
5 |
p. 652-660
|
artikel
|
| 4 |
Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
|
Smyth, E.C.
|
|
|
32 |
5 |
p. 590-599
|
artikel
|
| 5 |
Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19
|
Trojaniello, C.
|
|
|
32 |
5 |
p. 674-676
|
artikel
|
| 6 |
Claudin 18.2—a FAST-moving target in gastric cancer?
|
Athauda, A.
|
|
|
32 |
5 |
p. 584-586
|
artikel
|
| 7 |
Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy
|
Montopoli, M.
|
|
|
32 |
5 |
p. 676-677
|
artikel
|
| 8 |
Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis
|
Lach, K.D.
|
|
|
32 |
5 |
p. 679-681
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
32 |
5 |
p. iii
|
artikel
|
| 10 |
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
|
Sahin, U.
|
|
|
32 |
5 |
p. 609-619
|
artikel
|
| 11 |
High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications
|
Donnette, M.
|
|
|
32 |
5 |
p. 684-686
|
artikel
|
| 12 |
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
|
McGrail, D.J.
|
|
|
32 |
5 |
p. 661-672
|
artikel
|
| 13 |
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
|
Tempero, M.
|
|
|
32 |
5 |
p. 600-608
|
artikel
|
| 14 |
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
|
Felip, E.
|
|
|
32 |
5 |
p. 620-630
|
artikel
|
| 15 |
Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient
|
Hastings, R.K.
|
|
|
32 |
5 |
p. 681-684
|
artikel
|
| 16 |
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
|
Stinchcombe, T.E.
|
|
|
32 |
5 |
p. 587-589
|
artikel
|
| 17 |
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
|
Du, L.
|
|
|
32 |
5 |
p. 642-651
|
artikel
|
| 18 |
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
|
Spigel, D.R.
|
|
|
32 |
5 |
p. 631-641
|
artikel
|
| 19 |
Table of Contents
|
|
|
|
32 |
5 |
p. i-ii
|
artikel
|
| 20 |
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
|
Philip, P.A.
|
|
|
32 |
5 |
p. 582-583
|
artikel
|
| 21 |
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
|
Garassino, M.C.
|
|
|
32 |
5 |
p. 579-581
|
artikel
|
| 22 |
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
|
Peters, S.
|
|
|
32 |
5 |
p. 687-688
|
artikel
|
Tijdschrift beschrijving